Companies › Alume Biosciences
1 active drug program in 2 registered trials: 2 Phase 2; Oncology, Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Bevonescein Fluorescent imaging agent for nerve and tissue visualization | – | Phase 2 | Surgery; Head and Neck Disorder | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06662097 | Bevonescein | Phase 2 | Surgery | Other | Jan 2026 |
| NCT07631650 | Bevonescein | Phase 2 | Head and Neck Disorder | Oncology | Aug 2027 |
No annotated target.
–
Haihe Biopharma Monte Rosa Therapeutics Angitia NanoEcho Syncromune
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.